Suppr超能文献

十价或十三价肺炎球菌结合疫苗的引入对抗菌药物耐药性肺炎球菌疾病和携带的影响:系统文献综述。

The impact of the introduction of ten- or thirteen-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal disease and carriage: A systematic literature review.

机构信息

Murdoch Children's Research Institute, Melbourne, Victoria, Australia.

Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.

出版信息

J Glob Health. 2023 Feb 17;13:05001. doi: 10.7189/jogh.13.05001.

Abstract

BACKGROUND

A systematic review in 2019 found reductions in antimicrobial resistance (AMR) of pneumococcal vaccine serotypes following pneumococcal conjugate vaccine (PCV) introduction. However, few low- or middle-income countries were included as not many had introduced higher valent PCVs (PCV10 or PCV13). The aim of our review is to describe AMR rates in these samples following the introduction of PCV10 or PCV13.

METHODS

We conducted a systematic literature review of published papers that compared AMR for invasive pneumococcal disease (IPD), otitis media (OM) and nasopharyngeal carriage (NPC) samples following introduction of PCV10 or PCV13 to the pre-PCV period. Included studies published from July 2017 to August 2020 had a post-licensure observational study design and reported on our defined outcomes: IPD, OM, NPC and other (sputum or mixed invasive and non-invasive pneumococcal) isolates from people of all ages. Rates of AMR in the pre- and post-period were extracted.

RESULTS

Data were extracted from 31 studies. Among IPD isolates, penicillin AMR rates following PCV10 or PCV13 introduction declined in 32% (n = 9/29) of included studies, increased in 34% (n = 10/29) and showed no change in 34% (n = 10/29). Cephalosporins AMR declined in 32% (n = 6/19) of studies, increased in 21% (n = 4/19) and showed no change in 47% (n = 9/19). Macrolides AMR declined in 33% (n = 4/12) of studies, increased in 50% (n = 6/12), and showed no change in 17% (n = 2/12). AMR to other antibiotics (including multidrug resistance) declined in 23% (n = 9/39) of studies, increased in 41% (n = 16/39) and showed no change in AMR in 36% (n = 14/39). There were no obvious differences between AMR; in setting which used PCV10 vs PCV13, according to time since PCV introduction or by World Bank income status of the respective country. The only study including OM isolates found no change in penicillin resistance. There were few studies on AMR in NPC (four studies), OM (one study) or other isolates (five studies). The results followed similar patterns to IPD isolates.

CONCLUSIONS

We observed considerable heterogeneity in the findings between and within studies, e.g. no evidence of reduction in amoxicillin AMR with an increase in macrolides AMR. Reasons for such diverse findings include the period covered by different studies and variation in other pressures towards AMR.

摘要

背景

2019 年的一项系统评价发现,在使用肺炎球菌结合疫苗(PCV)后,肺炎球菌疫苗血清型的抗菌药物耐药性(AMR)有所降低。然而,由于许多低收入和中等收入国家尚未引入高价值的 PCV(PCV10 或 PCV13),因此很少有国家被纳入其中。我们的综述旨在描述在引入 PCV10 或 PCV13 后这些样本中的 AMR 率。

方法

我们对已发表的论文进行了系统的文献综述,这些论文比较了在引入 PCV10 或 PCV13 后,侵袭性肺炎球菌病(IPD)、中耳炎(OM)和鼻咽携带(NPC)样本中的 AMR。纳入的研究于 2017 年 7 月至 2020 年 8 月发表,采用上市后观察性研究设计,并报告了我们定义的结果:所有年龄段人群的 IPD、OM、NPC 和其他(痰或混合侵袭性和非侵袭性肺炎球菌)分离物。提取了报告的预 PCV 和 PCV 后时期的 AMR 率。

结果

从 31 项研究中提取了数据。在 IPD 分离物中,32%(n=9/29)的研究报告称,在引入 PCV10 或 PCV13 后,青霉素 AMR 率下降,34%(n=10/29)的研究报告称 AMR 率上升,34%(n=10/29)的研究报告称 AMR 率没有变化。头孢菌素的 AMR 下降了 32%(n=6/19),上升了 21%(n=4/19),没有变化的占 47%(n=9/19)。大环内酯类药物的 AMR 下降了 33%(n=4/12),上升了 50%(n=6/12),没有变化的占 17%(n=2/12)。其他抗生素(包括多重耐药性)的 AMR 下降了 23%(n=9/39),上升了 41%(n=16/39),36%(n=14/39)的 AMR 没有变化。根据使用 PCV10 与 PCV13 的情况、PCV 引入后的时间或各国的世界银行收入状况,我们没有发现 AMR 之间存在明显差异。唯一一项纳入 OM 分离物的研究发现,青霉素耐药性没有变化。关于 NPC(四项研究)、OM(一项研究)或其他分离物(五项研究)的 AMR 研究很少。结果与 IPD 分离物的结果相似。

结论

我们观察到研究之间和研究内部的结果存在相当大的异质性,例如,阿莫西林 AMR 没有下降,而大环内酯类 AMR 却有所增加。造成这种多样性结果的原因包括不同研究涵盖的时期以及对 AMR 的其他压力的变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53bb/9936452/6e15cf59d2a8/jogh-13-05001-F1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验